Your World, Fully Explored.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Conclave
Mother's Day
Met Gala
Baseball
Pope Francis
World War II
Social Media
Artificial Intelligence
Vatican
Real Estate
Donald Trump
Champions League
Published • loading... • Updated

Perioperative Pembrolizumab’s Strong Results for HNSCC Raise Questions

Summary by Medscape
The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and hopes for future innovations. Medscape Medical News

1 Articles

All
Left
Center
Right
MedscapeMedscape

Perioperative Pembrolizumab’s Strong Results for HNSCC Raise Questions

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and hopes for future innovations. Medscape Medical News

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medscape broke the news in United States on Tuesday, May 6, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Medical

Medical

News
For You
SearchBlindspotLocal